Share chart Aptevo Therapeutics Inc.
Extended chart
Simple chart
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc., биотехнологическая компания, работающая на клинической стадии, специализируется на разработке иммунотерапевтических кандидатов для лечения различных форм рака в Соединенных Штатах. Его ведущим клиническим кандидатом является APVO436, кандидат биспецифических Т-клеточных антител, который проходит фазу 1 / 1b клинических испытаний для лечения острого миелогенного лейкоза и миелодиспластического синдрома. Доклинические кандидаты компании также включают ALG. more detailsMain settings
| IPO date | 2016-07-20 |
|---|---|
| ISIN | US03835L2079 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | link |
| Change price per day: | -0.1452% (0.2754) |
|---|---|
| Change price per week: | -11.29% (0.31) |
| Change price per month: | -60.24% (0.6916) |
| Change price per 3 month: | -91.43% (3.21) |
| Change price per half year: | -97.79% (12.432) |
| Change price per year: | -61.32% (0.711) |
| Change price per 3 year: | -94.49% (4.99) |
| Change price per 5 year: | -95.61% (6.27) |
| Change price per year to date: | -93.76% (4.41) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 3.39 | 5 |
| P/BV | 0.2776 | 10 |
| P/E | 0.2476 | 10 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -119.36 | 0 |
| ROE, % | -284.28 | 0 |
| ROIC, % | -211.02 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -0.1947 | 10 |
| Debt/Ratio | 0.2969 | 10 |
| Debt/Equity | 2.28 | 6 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | -78.75 | 0 |
| Yield Ebitda, % | 45.48 | 6 |
| Yield EPS, % | 1570.83 | 10 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| Blackrock Inc. | 890 | 0.02 |
| Morgan Stanley | 194 | 0 |
| Qube Research & Technologies Ltd | 100 | 0 |
| Osaic Holdings Inc | 45 | 0 |
| JP Morgan Chase & Company | 43 | 0 |
| Wells Fargo & Company | 36 | 0 |
| Fifth Third Bancorp | 6 | 0 |
| PNC Financial Services Group, Inc. | 3 | 0 |
| Truvestments Capital, LLC | 2 | 0 |
| Tower Research Capital LLC (TRC) | 1 | 0.03 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Marvin L. White | President, CEO & Director | 841.39k | 1962 (63 years) |
| Ms. SoYoung Kwon J.D., LL.M. | Senior VP, General Counsel, Business Development & Corporate Affairs | 639.37k | 1969 (56 years) |
| Mr. Jeffrey G. Lamothe CA | Executive VP & COO | 722.51k | 1966 (59 years) |
| Dr. Dirk Huebner M.D. | Chief Medical Officer | N/A | 1963 (62 years) |
| Ms. Daphne L. Taylor | Senior VP & CFO | N/A | 1966 (59 years) |
About company
Address: United States, Seattle. WA, 2401 4th Avenue - Open in google maps, Open in yandex maps
Website: https://www.aptevotherapeutics.com
Website: https://www.aptevotherapeutics.com
